Newsletter · · Ashutosh Agarwal

Medicare Advantage Shrinks Again as Carriers Restore Broker Commissions - Managed Care Under Pressure - Week of September 26 – October 3, 2026

The Managed Care Under Pressure weekly podcast intelligence brief for the week of September 26 to October 3, 2026. The 2027 Medicare Advantage map shrinks again with roughly 3 million seniors forced to switch, twelve insurers exiting and HCSC halving its footprint, even as the two largest carriers restore broker commissions on slimmer plans, while regional plans attack the big insurers' risk scores, Medicare GLP-1 starts surge and insurer CEOs warn on January Medicaid work requirements across UnitedHealth, Humana, CVS, Cigna, Elevance, Centene and Molina.

Managed Care Under Pressure

Week of September 26 – October 3, 2026: Medicare Advantage Shrinks Again as Carriers Restore Broker Commissions

TL;DR

  • The 2027 Medicare Advantage map is out, and it is smaller again. On October 1, insurers were allowed to publicly market their 2027 plans. A Becker's payer reporter puts the number of seniors whose current plan disappears at around 3 million, "maybe even a little bit higher," matching last year. Twelve insurers are leaving Medicare Advantage entirely. About five dozen plans have capped how many members they will take, which is new this year. The biggest single pullback is the Blue Cross Blue Shield operator Health Care Service Corp. (HCSC), which is cutting its footprint from 950 counties to 450, one year after it bought Cigna's (CI) Medicare business for $3.3 billion.
  • The commission freeze is thawing. Last week brokers described carriers cutting off commissions to slow enrollment. This week the same broker podcast reported that "the two biggest carriers in the industry" are restoring commissions on plans across the country, now that the plans have been trimmed. For one of them, the share of plans that pay no commission fell by roughly 19.5% from 2026 to 2027. Read together, the pattern is: cut benefits and counties first, then reopen the sales channel on the slimmer plans. That is what a margin repair looks like.
  • Honest read on the week: still no investor voice. No podcast this week featured a sell-side or buy-side analyst making a call on UNH, HUM, CVS, ELV, CNC, MOH or CI. There was also nothing on UNH's September 30 contract deadline with NewYork-Presbyterian, the 2027 Star Ratings, the Justice Department's Medicare Advantage coding probe of UNH, or Q3 previews. What did fill in: a pointed attack on "outlier" risk scores at the big public insurers, new GLP-1 cost figures (Medicare GLP-1 starts reportedly at 700,000 seniors since July), and two insurer-side CEOs warning about Medicaid work requirements.

What's new

1. The 2027 Medicare Advantage landscape: roughly 3 million seniors must switch again, and plans are now turning members away

Jakob Emerson, who covers payers for Becker's (role: trade journalist), recorded on October 1, the day the industry's marketing embargo lifted. In his words: "today it's October 1st... Embargoes have lifted. Everything was public really early this morning."

His read on 2027:

  • Disruption on the same scale as last year. "Last year, it was about one in 10 people... close to 3 million people across the country. And... projections I'm seeing is around there, maybe even a little bit higher." He stressed these are projections and CMS will publish firmer numbers "within the next few weeks."
  • How plans are cutting. Insurers are "moving away from PPOs. They're going more towards HMOs because they can control the costs." (A PPO lets members see out-of-network doctors. An HMO limits members to a network and usually requires referrals, which makes costs easier to control.) They are cutting "side benefits" like "gym memberships... meal cards," but "dental, vision, hearing, that's all staying." And "they've cut broker commissions."
  • Enrollment caps are the new tool. "About five dozen or so plans... have also capped enrollments, which is a new thing this year... plans literally turning members away."
  • Growth is moving to special needs plans. These are plans for people who qualify for both Medicare and Medicaid (called "dual eligibles"), or for people with serious chronic conditions. Insurers keep building there because "it's a lot more profitable for them... But the PPO of the past is definitely disappearing."
  • Who is leaving. "There's 12 insurers overall that are going to be exiting." Eight of them are plans owned in whole or in part by hospital systems. Some have only "10, 15,000 people," though a few, like Providence's, are in "the hundreds of thousands." His conclusion is that only the strongest provider-owned plans, "Kaiser, UPMC, Intermountain with Select Health," seem able to get through "this really difficult period for the entire insurance industry."

Becker's Healthcare Podcast, "Medicare Advantage Shifts and AI's Growing Role in Health Insurance with Jakob Emerson" (2026-10-01)

The single biggest retreat was reported by Crain's Daily Gist (role: business journalists). HCSC, which runs Blue Cross and Blue Shield plans in five states, "is cutting its Medicare Advantage footprint in half for 2027. The insurer will drop coverage from 950 counties down to 450, scaling back from 31 states to 24." That comes "just one year after HCSC made a massive push into the national Medicare market, acquiring Cigna's Medicare business for $3.3 billion." Crain's attributed the industry-wide pullback to "surging medical costs, lower federal payment rates, and reduced quality bonuses from Medicare's star ratings system." Crain's Daily Gist, "Illinois has talent. Does it have the capital to keep it?" (2026-10-02)

On Humana specifically, the host of The 9Innings Podcast, a financial adviser who is regularly quoted in the press (role: pundit), noted that "Humana recently announced that it would be discontinuing Medicare Advantage plans affecting hundreds of thousands of members," adding that when competition drops, it doesn't always show up as a premium increase: "Maybe the provider network becomes narrower. Maybe certain supplemental benefits disappear." The 9Innings Podcast, "FoF: Behind the Headlines: What the Financial News Isn't Telling You." (2026-09-29)

Why it matters: For the public insurers, this is the bull case playing out. Fewer counties, fewer PPOs, slimmer extras and capped enrollment all point to a lower medical loss ratio (the share of premium paid out in medical claims) in 2027. HCSC's retreat is notable because it reverses a $3.3 billion bet made just a year ago; CI sold that business at the right time. The risk is that a third straight year of roughly 3 million forced switches keeps Medicare Advantage disruption in front of politicians heading into the midterms.

2. The broker channel is reopening: "the two biggest carriers" are restoring commissions

On The Seven Figures Or Bust Podcast!, hosted by independent Medicare agents (role: distribution/agents, not investors), the hosts pushed back hard on agents who had predicted the end of broker commissions. Their argument is that carriers were always going to cut first and then reopen:

  • "Plans need to terminate out, can't happen all at once. Plan benefits need to slash, can't happen all at once. And levers need to be pulled to control enrollment, like suppression, like non-commissionable plans."
  • "Going into this AEP, we have close to 3 million SARs." (AEP is the annual enrollment period, October 15 to December 7. A SAR, or service area reduction, means a plan stops being offered in a county.) "Many of those were previously non-commissionable plans."
  • "The two biggest carriers in the industry this month announced that they are recommissioning plans all across the country in several markets." The hosts would not name them ("I can't mention any carriers' names... Who are the two biggest carriers in the industry?"). By enrollment, the two largest Medicare Advantage carriers are UnitedHealthcare (UNH) and Humana (HUM), but that identification is our inference, not the hosts' statement.
  • For the carrier whose commission schedule came out that Monday, the host compared 2026 with 2027 and found "a reduction in total plans that are non-commissionable by 19.5%, give or take 19 to 20%." The same document restored full commission when an agent moves a member from one of the carrier's plans to another, which had previously paid only "a very limited partial commission." He scored it "8 out of 10."
  • The carrier also kept existing renewal commissions on stand-alone Part D drug plans intact, despite speculation it would pull them.

The Seven Figures Or Bust Podcast!, "Episode 277 - Several Carriers Recommission Plans In Many States! (Chicken Littles Take An L)" (2026-09-30)

In an episode two days earlier, the same hosts described carriers getting much pickier about which agents they work with, because agent quality now feeds directly into Star Ratings (Medicare's 1-to-5-star quality score, which determines bonus payments). Carriers are terminating agents whose clients don't stay; one example used a "75% retention minimum." They are also pushing agents to complete health risk assessments and list a primary care doctor on every application, because these "help with their star ratings, which is more important than ever." Agents cut for low production are being told they "can't recontract for the rest of the year," which the host called "a new thing entirely." The hosts also estimated that the big online call-center brokers (eHealth, GoHealth, SelectQuote) once "potentially combined for like 15% of annual enrollments" and said GoHealth was reportedly "officially shutting their doors." Treat that last point as the hosts' report; we have not verified it. The Seven Figures Or Bust Podcast!, "Episode 276 - Medicare Advantage Sales Have Changed (Here's How)" (2026-09-28)

Why it matters: This is a real update to last week. Last week's evidence showed carriers using commission cuts as a brake on sign-ups. This week shows the brake coming off, but only on plans that have already been trimmed. For UNH and HUM, that suggests 2027 is shaping up as a year of controlled growth on better-priced plans, not a year of shrinking at any cost. The move away from high-churn call centers toward agents who keep members and help with quality scores also supports Star Ratings over time.

3. Regional plans take aim at the big insurers' risk scores

Ceci Connolly, CEO of the Alliance of Community Health Plans (ACHP), the trade group for nonprofit regional plans (role: industry association / policy), went further than usual in criticizing the large public insurers.

  • Last year's disruption, measured. ACHP's research with HealthScape found that in 2026 there was "a 10% decline in nationwide MA plan count. That impacted 4.6 million Medicare Advantage beneficiaries who were informed, you can't stay with your current plan." (That is a broader measure than the roughly 3 million cited by Becker's and last week's sources, which likely counts only people whose plan was fully discontinued. The podcasts did not reconcile the two.)
  • The accusation. Risk adjustment pays plans more for sicker members based on the diagnoses they record. Connolly said ACHP's analysis found "outliers that are collecting billions dollars more... One or two of the national publicly traded companies are having significantly higher scores. And you really have to take a look and question what's going on there in that data." She did not name the companies.
  • The ask. ACHP wants CMS to move toward "an inferred risk model that is going to take the coders out of the equation," setting payment from doctor visits, filled prescriptions and lab work rather than from diagnosis codes.
  • Two regulatory wins already. CMS has given plans the ability "to put some enrollment caps in place" and some flexibility on risk adjustment for members who "arrive somewhat unexpectedly," whose health records a plan may not see "for up to 18 months."
  • The outlook. Asked if more exits are coming from the big plans: "Yes, in a word... those publicly traded companies, they answer to Wall Street. Our member plans, they answer to Main Street." Her nonprofit members are "thrilled if they have a 1% to 2% margin."

Becker's Payer Issues Podcast, "Medicare Advantage Market Disruption and the Future of Risk Adjustment with Ceci Connolly" (2026-09-30)

Why it matters: This is lobbying, not a finding, and it should be read that way. But it lines up with the Justice Department's coding probe of UNH and with the V28 risk-model change that was fully phased in this year. A move to an "inferred" risk model would take away the coding edge that the most sophisticated insurers have built. The fact that CMS has already granted enrollment caps shows the agency is listening to this group. Separately, both the enrollment-cap flexibility and the 18-month risk-adjustment lag help explain why insurers can now turn away members from failed competitors without as much penalty.

4. GLP-1s: 700,000 new Medicare starts since July, and employers keep pulling back

The weight-loss drug story kept moving toward the payer's side of the ledger.

  • Medicare uptake. Telltales, an AI-voiced market news podcast (role: pundit/automated news, secondhand), relayed Eli Lilly CEO Dave Ricks's recent TV comments: "700,000 new seniors have started GLP-1s since Medicare coverage opened in July, and 70% of them picked Lilly." Treat the figure as Ricks's claim as reported, not something we have checked against CMS data. Telltales, "Weekend Update - W2639" (2026-09-27)
  • The bridge program's terms. On The Dr. Francavilla Show, host Dr. Francavilla and obesity physician Dr. Melanie Jay (role: clinicians) said eligible Medicare Part D patients can get GLP-1s "for like $50 a month," versus "$500 or more per month" elsewhere, and that the bridge program "goes through the end of 2027." The Dr. Francavilla Show, "Wegovy, Zepbound and Obesity Care for Older Adults With Dr. Melanie Jay" (2026-09-28) A patient-advocacy podcast confirmed the bridge requires an existing Part D or Medicare Advantage drug plan, and that approval can still take more than one try. One guest was "denied with regular Medicare... the second time with the bridge program denied, the third time accepted for a year." The Plus SideZ, "GLP-1 Denied to Approved: Medicare Bridge Part 2" (2026-09-30)
  • The employer bill. On This Time Is Different, a general business and markets show (role: pundits), the hosts cited Bank of America CEO Brian Moynihan saying the bank "spends $250 million a year on GLP-1 weight loss drugs," now "more than 10% of the company's entire healthcare budget," up "from $0 a few years ago." They also cited a National Bureau of Economic Research study finding that each dollar of GLP-1 spending "generates an additional 22 cents in non-GLP-1 spending," mostly outpatient care, over five years. That is the opposite of the hoped-for savings. They said Cigna and PepsiCo "just slowed down or discontinued GLP-1 coverage on their plans"; this appears to refer to the companies as employers, and we have not verified it. This Time Is Different, "Will Healthcare Costs Take More Jobs Than AI?" (2026-09-29)
  • Drugmakers are routing around insurers. On STAT's The Readout Loud (role: biotech journalists), a STAT biotech reporter said Novo Nordisk now explicitly markets its drugs as "weight loss drugs" with slogans like "Live Lighter" and "Summer Glow Up," because "insurance coverage has stalled, they've increasingly turned to the direct-to-consumer channel." The Readout Loud, "415: Mistrust in science and a juicy gene-editing lawsuit" (2026-10-01)

Why it matters: Two different payer stories are running at once. In commercial insurance, employers are deciding the drugs cost too much and are pulling coverage, which lowers volume at PBMs (pharmacy benefit managers, the companies that run drug plans for employers and insurers) like CVS's Caremark, Cigna's Express Scripts and UNH's Optum Rx. In Medicare, a government bridge program at $50 a month is driving a surge in senior starts. How much of that bridge cost lands on Part D and Medicare Advantage plans, versus the government, is still the key open question; none of this week's podcasts answered it.

5. Medicaid work requirements: insurer CEOs expect people to fall through the cracks

Karen Ignagni, CEO of New York's EmblemHealth and former head of the insurer trade group AHIP (role: operator, insurer CEO), was blunt about the January 1, 2027 Medicaid work requirements and the expired enhanced ACA subsidies.

  • On preparing members: "It's a full court press here... it's very, very unclear as to which individuals can get exemptions. For example, on work requirements, if you have cancer, you don't have an automatic exemption. That's a head scratcher to me."
  • On what comes next: "I'm very worried about people falling out of the system. I'm worried about bad debts... I think we're going to see a number of people falling out," and the fallout "will flow up to the national level as we head into a presidential election."
  • On subsidies: the host noted the administration "would send $500 checks to nearly 1 million Americans in states using the federal exchange." Ignagni said whether that is adequate "will be the kitchen table test for many families."
  • On what is driving costs: she cited a Yale study in JAMA finding that rising unit prices "fueled 90% of the growth in expenditures from 2011 to '24," with "hospitals that are over 400% of Medicare," and proposed a medical loss ratio rule for hospitals and drug companies like the one insurers face.

Becker's Payer Issues Podcast, "Karen Ignagni on Affordability, Medicaid and the Future of Health Insurance" (2026-09-29)

Dr. Toyin Ajayi and Mike Roaldi of Cityblock Health, a value-based care company serving Medicaid members (role: operators), offered a useful counterpoint on who actually gets cut. After the pandemic-era Medicaid redeterminations, "probably on the order of 15 to 20 million people ultimately no longer qualified." On work requirements, Cityblock expects less damage to its own book: "because our cohorts tend to be more acute, a higher percentage of them are going to be exempt." Health Care Rounds, "The Trust-First Model Transforming Medicaid Care w/ Dr. Toyin Ajayi & Mike Roaldi, Cityblock" (2026-10-02)

Why it matters: The Cityblock point is the key one for CNC and MOH. Work requirements are designed to remove healthier, working-age adults; the sickest members are more likely to be exempt. That means the members who leave are more likely to be the profitable ones, and the remaining pool skews sicker. Unless states raise rates to match, that pushes Medicaid margins down through 2027. Ignagni's point about bad debt matters for hospitals, too.

Smaller items worth knowing

  • UNH is building an AI front door. Emerson reported that UnitedHealthcare has launched "Avery," described "as their answer to Siri," which can "call the doctor for you... book the appointment." The goal was to reach 20 million members across employer, Medicare and Medicaid plans by year-end, out of "over 50 million." Aetna (CVS) is doing something similar but is "a little bit behind." His point was that only the largest insurers can afford this, which is "more bad news for the small guys." Becker's Healthcare Podcast, Emerson (2026-10-01)
  • Cigna's specialty pharmacy pitch. A pharmacy trade news segment reported that at Cigna's 2026 Investor Day, the company "identified a specialty pharmacy and care services market approaching $500 billion, with Accredo and its specialty operations positioned as major growth drivers." Pharmacy Podcast Network, "Independent Pharmacy: AI, Consolidation & Fighting for Every Dollar | TWIRx" (2026-10-02)
  • Dual eligibles switch plans a lot. A USC Schaefer Center study discussed on AJMC's podcast found that among people fully eligible for both Medicare and Medicaid, switching from one Medicare Advantage plan to another rose from about 12% in 2016 to about 22% in 2022. These members were about six times more likely to switch to another MA plan than to traditional Medicare. That fits with insurers pushing into special needs plans: these members are valuable, but they also churn. Managed Care Cast, "MA Switching Surges Among Dually Eligible Adults: Grace Mackleby, PhD" (2026-09-29)
  • CMS's international drug-pricing test shrank to almost nothing. The Pink Sheet's podcast reported that CMS finalized its GLOBE model (international reference pricing for Medicare Part B drugs) but exempted companies that signed "most favored nation" deals with the administration. That left "only about four manufacturers," and projected savings fell to "$400 million over the seven years" from "$11.9 billion" in the proposal. A related Part D model (GUARD) is still pending; the proposal acknowledged it would save Medicare money but "raise costs for beneficiaries," so it may wait until after the elections. Citeline Podcasts, "Drug Fix: CMS Finalizes GLOBE Model And US FDA Adcomm, Personnel Changes" (2026-10-02)
  • Consumer shows expect higher 2027 Medicare costs. On Friends Talk Money (role: consumer finance hosts), the hosts said the Part B premium is expected to rise "a little over 3%" to "about $209 a month" (not yet officially announced at recording), that Medigap premiums have been rising "10%, 20%, sometimes 40%" in many cases, and that Part D premiums "are going to be going up 6% in 2027." These are the hosts' figures, not official CMS releases. Friends Talk Money, "Medicare Open Enrollment 2027: Premiums, Part D & the Advantage Plan Crisis (Part 1 of 3)" (2026-09-28)
  • Employer premiums could jump. Consumer advocate Clark Howard (role: pundit) told listeners employer premiums "could be 20% next year" in states with more uninsured people and "10 or so percent" elsewhere, blaming hospitals passing on the cost of uncompensated care and "a concentration of power in medicine city by city of major hospital systems." The Clark Howard Podcast, "10.02.26 Clark Answers His Critics on Clark Stinks / Health Insurance Sticker Shock" (2026-10-02)

The debate

The bull case: the repair is working, and 2027 is the payoff year. The evidence this week fits the bull case well. Insurers have now had two seasons to cut unprofitable counties (around 3 million forced switches each year), drop PPOs for HMOs, trim extras like gym and meal cards, and use enrollment caps that CMS itself has allowed. The fact that the two largest carriers are now restoring broker commissions is the strongest sign yet that they think their 2027 plans are priced to make money. If they didn't, they would keep the brakes on. V28 is fully phased in, so 2027 is the first year without a new risk-model cut. Competitors are leaving (HCSC halving its footprint, 12 insurers exiting), which leaves more pricing power for the national players. And the industry is investing in quality, from agent retention rules to AI assistants, that should support Star Ratings.

The bear case: margins are being rebuilt on a shrinking, more political base. Three straight years of millions of seniors losing their plans is a political story, and the people telling it now include the regional insurers' own trade group, which is openly pointing at "one or two of the national publicly traded companies" for outlier risk scores and asking CMS to "take the coders out of the equation." If that idea gains traction, it would hit the companies that have invested most in coding. Medical costs are not easing. Crain's still blames "surging medical costs" for the exits, Ignagni says unit prices drove 90% of spending growth, and the Medicare GLP-1 bridge is adding hundreds of thousands of new users. Medicaid work requirements start January 1 and are likely to remove healthier members first. Exchange enrollment faces expired subsidies plus last week's agent freeze. And still, no investor podcast this week offered numbers to show where 2027 earnings land.

Where we come out: The direction for Medicare Advantage margins in 2027 looks better than it did a year ago, and this week's commission news is the clearest operating signal yet. But the political and risk-adjustment threats are growing, not fading, and the Medicaid and exchange books (CNC, MOH, part of ELV) look worse into 2027 than the Medicare books.

Stocks in play

UNH (UnitedHealth Group)

  • Bull: Likely one of the "two biggest carriers" restoring commissions (our inference), which points to confidence in 2027 pricing. Scale advantages are widening, such as the Avery AI assistant reaching 20 million members, with smaller and hospital-owned plans exiting.
  • Bear: The most obvious target of ACHP's "outlier" risk score charge and of any shift to an inferred risk model, on top of the DOJ coding probe. Still no podcast coverage of the NewYork-Presbyterian contract outcome.
  • Next catalyst: Q3 FY2026 results on October 13 (before open). Watch Medicare Advantage medical cost trend, 2027 membership commentary, and any update on NYP.

HUM (Humana)

  • Bull: The other likely large carrier restoring commissions; the purest beneficiary of V28 being fully phased in and of competitors leaving.
  • Bear: Named by a commentator as discontinuing plans affecting "hundreds of thousands of members," which keeps it at the center of the disruption story. Most exposed to Star Ratings, which got no podcast coverage this week.
  • Next catalyst: 2027 Star Ratings (expected in October); AEP opens October 15; Q3 FY2026 on November 6.

CVS (CVS Health / Aetna)

  • Bull: Aetna is building an AI member assistant like UNH's; Caremark scale.
  • Bear: Behind UNH on AI ("a little bit behind"); employer GLP-1 coverage pullbacks reduce PBM volume; last week's reported Tennessee PBM-ownership lawsuit still has no follow-up.
  • Next catalyst: Q3 FY2026 on October 28.

CI (Cigna)

  • Bull: Sold its Medicare business to HCSC for $3.3 billion a year before the buyer cut that footprint in half; the timing looks very good in hindsight. Investor Day framed a specialty pharmacy market "approaching $500 billion," with Accredo as a growth driver.
  • Bear: Express Scripts is exposed to employers dropping GLP-1 coverage; Cigna itself was cited (unverified) as slowing GLP-1 coverage as an employer.
  • Next catalyst: Q3 FY2026 on October 29.

ELV (Elevance Health)

  • Bull: Diversified across commercial, Medicare and Medicaid; benefits from regional and provider-owned competitors leaving MA.
  • Bear: Exposed on all three fronts: Medicaid work requirements, exchange subsidy loss and the agent freeze, and MA benefit cuts. No ELV-specific podcast news.
  • Next catalyst: Q3 FY2026 on October 20.

CNC (Centene)

  • Bull: If work requirements and the agent freeze remove fraud and low-use members, a smaller but cleaner book is possible.
  • Bear: Cityblock's point cuts the other way: the sickest members are more likely to be exempt, so the members who leave are more likely to be the healthier, profitable ones. Most exposed to the ACA exchange as well.
  • Next catalyst: Q3 FY2026 on October 27; ACA open enrollment begins November 1 under the agent freeze.

MOH (Molina Healthcare)

  • Bull: Most levered to any state Medicaid rate catch-up; growing in dual-eligible products, where switching is high but margins are attractive.
  • Bear: Most levered to work-requirement enrollment losses and the sicker remaining pool that Ignagni and Cityblock describe.
  • Next catalyst: Q3 FY2026 on October 22; 2027 state rate updates.

Adjacent: HCSC (private, not listed). The biggest MA retreat of the year (950 to 450 counties, 31 to 24 states). Its exiting members are available to UNH, HUM, ELV and CVS, but carriers have shown they will turn away members they consider too sick.

Read-throughs

Medicaid and exchange insurers (CNC, MOH). This week added the mechanism behind the risk. Work requirements start January 1, 2027, and two operators agreed exemptions will be messy (cancer isn't an automatic exemption) and that sicker members are more likely to be exempt. That means a smaller and sicker Medicaid pool. On the exchange side, $500 checks to about 1 million federal-exchange enrollees are a partial offset to the expired subsidies, but Ignagni doubts they are enough. No podcast this week covered 2027 state Medicaid rates.

PBMs and Optum-style services arms. Employer GLP-1 pullbacks (Bank of America's $250 million bill; Cigna and PepsiCo cited as cutting back) and Novo's turn to selling directly to consumers both reduce the GLP-1 volume running through Caremark, Express Scripts and Optum Rx. Cigna is pointing investors to specialty pharmacy instead. The shrunken GLOBE model and a still-pending Part D pricing model suggest the administration is using drug-pricing rules mainly as leverage for direct deals with drugmakers.

Hospitals and providers. Providers are on both sides this week. Eight of the 12 insurers leaving Medicare Advantage are hospital-owned plans, which shows how hard the business has become for systems without Kaiser-like scale. Safety-net systems are under strain: Craig Wagoner, CEO of California's Community Health System, said his system ranks "second nationally in the percentage of Medicaid volume," has "been operating in the red for some time," and is aiming to be "back in the black by the end of '29." 13th & Park, "Can a Safety Net Hospital Be the Model for American Healthcare? | Craig Wagoner on 13th & Park" (2026-10-02) Insurer leaders like Ignagni are now openly blaming hospital prices, which points to tougher contract talks. The UNH-NewYork-Presbyterian dispute is the obvious test case, but no podcast covered how it ended.

GLP-1 cost exposure. For commercial plans, the pressure is easing as employers drop coverage. For Medicare, it is growing: 700,000 new senior starts since July (per Lilly's CEO, as relayed) at a $50 monthly copay through 2027. The NBER finding that each GLP-1 dollar brings another 22 cents of other spending over five years undercuts the "it pays for itself" argument. The unanswered question remains how much of the bridge cost falls on Part D and Medicare Advantage plans.

What changed vs. last week

  • Updated, in the bull direction: commissions. Last week, brokers described carriers refusing to pay commissions to slow sign-ups ("this is how we're going to curb enrollments"). This week, the same broker show reported the two biggest carriers restoring commissions across many markets, with one carrier's share of no-commission plans down about 19.5% for 2027. The cutbacks happened; the channel is reopening on slimmer plans.
  • Confirmed and sized: 2027 MA disruption. Last week's ">2 million" seniors facing 2027 terminations is now "around 3 million, maybe even a little bit higher" per Becker's, with 12 insurers exiting, about 60 plans capping enrollment, and HCSC halving its footprint. ACHP put last year's impact at 4.6 million beneficiaries, a broader measure than the 3 million used elsewhere.
  • New: a direct attack on risk scores. ACHP's "outlier" claim against "one or two" public insurers and its push for an inferred risk model is a new front, building on last week's V28 study.
  • Advanced: GLP-1. It moved from employer carve-outs (last week) to hard Medicare uptake numbers (700,000 starts, as relayed) and confirmation that the $50 bridge runs through 2027.
  • Advanced: Medicaid work requirements. From last week's enrollment estimates to how the exemptions will actually work, and why the remaining pool is likely to be sicker.
  • Still absent: any human sell-side or buy-side analyst on these stocks (two weeks running); the UNH-NewYork-Presbyterian September 30 outcome; the UNH DOJ/RADV probe; Star Ratings and Stars litigation; Optum or CVS strategic reviews; Q3 pre-announcements; follow-up on the reported CVS-Tennessee PBM lawsuit; any carrier-level GLP-1 coverage decision for Medicare Advantage.

Coming up: 2027 Star Ratings (October); UNH Q3 FY2026 on October 13; AEP opens October 15; ELV October 20; MOH October 22; CNC October 27; CVS October 28; CI October 29; ACA open enrollment begins November 1 under the agent freeze; HUM November 6; Medicaid work requirements begin January 1, 2027.